Metformin: An Update

@article{Kirpichnikov2002MetforminAU,
  title={Metformin: An Update},
  author={Dmitri Kirpichnikov and Samy I McFarlane and James R Sowers},
  journal={Annals of Internal Medicine},
  year={2002},
  volume={137},
  pages={25-33}
}
Insulin resistance contributes greatly to development of cardiovascular disease in patients with the metabolic syndrome and its extreme presentation, type 2 diabetes mellitus. Therefore, treatment with an insulin-sensitizing agent, such as metformin, in patients with type 2 diabetes mellitus may correct several of the primary pathophysiologic abnormalities of the metabolic syndrome. In diabetic patients, metformin appears to provide cardiovascular protection that cannot be attributed only to… Expand
Use of Metformin in Patients with Kidney and Cardiovascular Diseases
TLDR
The use of metformin in patients with kidney disease, a high-risk CVD state, is confounded by confusion regarding appropriate concerns about the development of lactic acidosis in this population. Expand
Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes
TLDR
The clinical data behind the use of metformin in combination with TZDs for the management of diabetes, its impact on vascular health, side effects and potential mechanisms of action for combined use are reviewed. Expand
Metformin: new understandings, new uses.
TLDR
The role of metformin in the treatment of patients with type 2 diabetes and its potential role for a variety of insulin resistant and prediabetic states, including impaired glucose tolerance, obesity, polycystic ovary syndrome and the metabolic abnormalities associated with HIV disease are reviewed. Expand
Metabolic syndrome therapy: Prevention of vascular injury by antidiabetic agents
TLDR
The oral agents used to treat type 2 diabetes and the metabolic syndrome, and their effects on vascular tissue are reviewed, including metformin, thiazolidinediones, which target insulin resistance. Expand
Insulin Sensitizers and Cardiovascular Disease
TLDR
Thiazolidinediones (TZDs) decrease IR primarily at the level of the muscles, thereby increasing glucose uptake and decreasing plasma glucose and may improve insulin sensitivity by decreasing the plasma free fatty acid concentration (FFA). Expand
A preclinical overview of metformin for the treatment of type 2 diabetes.
TLDR
The pharmacological function of metformin in lowering hyperglycemia suggests that multi-targeting could be an effective strategy for the discovery of new anti-diabetic drugs. Expand
Reducing insulin resistance with metformin: the evidence today.
TLDR
The therapeutic profile of metformin supports its use for the control of blood glucose, in diabetic patients and for the prevention of diabetes in subjects with impaired glucose tolerance, and the improvement by met formin of cardiovascular risk factors associated with the dysmetabolic syndrome may account for the significant improvements in macrovascular outcomes observed in the UK Prospective Diabetes Study. Expand
Individualized Therapy for Type 2 Diabetes
TLDR
The current understanding of genetic polymorphisms that may affect the responses of subjects with T2DM to antidiabetic treatment is summarized and three major classes of genes involved in drug metabolism and transporters that influence pharmacokinetics are summarized. Expand
Metformin, beyond an insulin sensitizer, targeting heart and pancreatic β cells.
TLDR
The beneficial role of metformin not only protects T2DM patients from cardiovascular diseases and heart failure, but also restores insulin secretion activities and protects pancreatic β cells from lipotoxicity or glucotoxicity. Expand
Insulin sensitisation in the treatment of Type 2 diabetes
TLDR
Novel approaches to insulin sensitisation will not only provide effective long-term glycaemic control but improve cardiovascular outcomes in Type 2 diabetes, according to the newly-marketed thiazolidinedione insulin-sensitising antidiabetic agents. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 101 REFERENCES
An overview of metformin in the treatment of type 2 diabetes mellitus.
TLDR
Metformin is safe and effective both as monotherapy or in combination with other antihyperglycemic agents in type 2 diabetic patients requiring additional glycemic control and may be advantageous when weight control is desirable and/or hyperlipidemia exists. Expand
The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms.
TLDR
Metformin improves hepatic and peripheral sensitivity to insulin, with both direct and indirect effects on liver and muscle, which collectively reduce insulin resistance and glucotoxicity in type 2 diabetes. Expand
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
TLDR
Metformin monotherapy and combination therapy with metformin and sulfonylurea are well tolerated and improve glycemic control and lipid concentrations in patients with NIDDM whose diabetes is poorly controlled with diet or sulfonyLurea therapy alone. Expand
Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
TLDR
Metformin and troglitazone have equal and additive beneficial effects on glycemic control in patients with type 2 diabetes. Expand
Combining sulfonylureas and other oral agents.
  • M. Riddle
  • Medicine
  • The American journal of medicine
  • 2000
TLDR
Later in the course of the disease, the use of combinations of oral agents may delay the need for insulin while maintaining glycemic control, thus making aggressive oral treatment more acceptable for many patients. Expand
Acute Antihyperglycemic Mechanisms of Metformin in NIDDM: Evidence for Suppression of Lipid Oxidation and Hepatic Glucose Production
TLDR
The specific, antihyperglycemic effects of metformin in the clinical condition of hyperglycemia in NIDDM are primarily due to suppression of HGP, not stimulation of glucose uptake, and are mediated, at least in part, by suppression of FFA and lipid oxidation. Expand
Mechanism by which metformin reduces glucose production in type 2 diabetes.
TLDR
Patients with poorly controlled type 2 diabetes have increased rates of endogenous glucose production, which can be attributed to increased levels of gluconeogenesis, according to the differences between the two methods used. Expand
Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
TLDR
The data suggest that combination treatment with once-daily metformin-rosiglitazone improves glycemic control, insulin sensitivity, and beta-cell function more effectively than treatment with met formin alone. Expand
Diabetes mellitus and diabetes-associated vascular disease
TLDR
Tight glycemic control, the treatment of dyslipidemia and raised blood pressure, in addition to the use of antiplatelet therapy, all powerfully reduce the risks associated with diabetes and angiotensin-converting enzyme inhibitors might offer additional cardioprotection above that provided by blood pressure reduction. Expand
Disparate effects of antidiabetic drugs on arterial contraction.
TLDR
Results are consistent with measures of vascular function obtained in the past after oral administration of the drugs, which suggested but did not prove that they may exert direct effects on arterial vascular contractility, but metformin and thiazolidinediones may decrease arterial pressure partly by direct vasorelaxant mechanisms. Expand
...
1
2
3
4
5
...